ArticleCureus2025
When Falls Reveal Acidosis: Unmasking Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Euglycemic diabetic ketoacidosis (euDKA) is a rare but serious complication of diabetes mellitus, consisting of about 3% of DKA presentations, and often associated with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Unlike classic DKA, euDKA presents with ketoacidosis despite normal or only mildly elevated blood glucose levels, which can delay diagnosis and treatment. We report the case of a 77-year-old woman with insulin-dependent type 2 diabetes who presented after multiple unprovoked falls that appear to be multifactorial in origin. Initial evaluation revealed dehydration, mild hyperglycemia (glucose 183 mg/dL), elevated anion gap, and positive urine ketones and glucose. Despite treatment with intravenous (IV) fluids and subcutaneous insulin, her condition worsened over the next 24 hours, with progressive acidosis (bicarbonate <10 mmol/L, arterial pH <7.00) and glucose levels remaining below 250 mg/dL. EuDKA was diagnosed, but the patient was unstable and was moved to the ICU. Dapagliflozin was discontinued, and she was treated successfully with IV insulin and aggressive fluid resuscitation. This case illustrates the importance of maintaining a high index of suspicion for euDKA in elderly patients on SGLT2 inhibitors, particularly when presenting with nonspecific symptoms such as confusion or falls. Early recognition, prompt discontinuation of the SGLT2 inhibitor, and appropriate management are critical to improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.